



GENERAL OVERVIEW OF TUBERCULOSIS: CAUSES, SYMPTOMS, AND RISK FACTORS

Narmetova Yulduz Karimovna

Associate Professor at Tashkent State Medical University

Doctor of Psychological Sciences (DSc)

Rustamov Shohrux O'tkirovich

Student at Tashkent State Medical University

Abstract

Tuberculosis (TB) remains a global health threat, exacerbated by factors such as drug resistance, co-infections, and social determinants of health. This comprehensive review examines various aspects of TB, including epidemiology, pathophysiology, diagnosis, treatment, prevention, and control measures. The bacterium *Mycobacterium tuberculosis* causes TB and primarily affects the lungs, although it can also affect other organs. Risk factors for TB include poverty, malnutrition, overcrowded living conditions, and immunocompromised states such as HIV/AIDS. Symptoms of TB include cough, fever, weight loss, and night sweats, but can vary depending on the site of infection. Diagnosis typically involves clinical evaluation, imaging studies, and microbiological testing, with rapid molecular tests such as the Xpert MTB/RIF assay revolutionizing TB diagnostics. Treatment consists of multidrug therapy for six to nine months, with drug-resistant TB requiring longer and more complex regimens. Prevention and control efforts focus on early case detection, treatment adherence, infection control measures, and Bacille Calmette-Guérin (BCG) vaccine vaccination. TB research and innovation aim to develop new diagnostics, drugs, and vaccines to improve TB control and treatment outcomes. Challenges to TB control include stigma, healthcare access barriers, and the rise of drug-resistant TB strains. Collaboration and advocacy efforts are essential for addressing TB in special populations, high-risk settings, and co-infection scenarios. Integrating a One Health approach, harnessing technology, and



addressing climate change impacts is critical for advancing TB control efforts and achieving the goal of ending.

Keywords: Tuberculosis; epidemiology; diagnosis; treatment; prevention.

Introduction

Tuberculosis (TB) has long been recognized as one of the most ancient and persistent infectious diseases afflicting humanity. Mycobacterium tuberculosis's etiological agent has haunted human populations for millennia, shaping societies and influencing historical events. Despite significant strides in medical science and public health, TB remains a formidable global health challenge, affecting millions of individuals worldwide each year.

This transmission mode underscores the significance of close human contact and shared airspace in facilitating the spread of the disease. Factors such as overcrowded living conditions, TB is primarily transmitted through the inhalation of airborne droplets containing M. tuberculosis, typically expelled when an infected person coughs, sneezes, or speaks. Inadequate ventilation, and compromised immune systems further exacerbate the risk of TB transmission. The clinical manifestations of TB are diverse and can vary depending on factors such as the route of infection and the individual's immune status. Common symptoms include a persistent cough, fever, fatigue, and weight loss. However, TB can also affect other organs besides the lungs, leading to extrapulmonary manifestations such as lymphadenitis, pleuritis, and meningitis.

Various risk factors predispose individuals to TB infection and disease progression. Immunocompromised conditions, such as HIV/AIDS, malnutrition, and diabetes, significantly increase susceptibility to TB. Additionally, socioeconomic determinants such as poverty, homelessness, and inadequate access to health care contribute to the burden of TB, particularly in vulnerable populations.



EPIDEMIOLOGY

Tuberculosis (TB) continues to be a global health concern, with significant implications for public health and healthcare systems worldwide. Despite concerted efforts to control the disease, TB remains a leading cause of morbidity and mortality, particularly in low-and middle-income countries. According to the World Health Organization (WHO), an estimated 10 million people developed TB in 2019, with approximately 1.4 million deaths attributed to the disease.

The emergence of drug-resistant TB poses a significant challenge to TB control efforts. Multidrug-resistant TB (MDR-TB), defined as resistance to at least isoniazid and rifampicin, is of particular concern due to its limited treatment options and poorer prognosis. According to WHO estimates, there were approximately 465,000 cases of MDR-TB worldwide in 2019, with the highest prevalence observed in Eastern Europe and Central Asia. Extensively drug-resistant TB (XDR-TB), characterized by resistance to fluoroquinolones and second-line injectable drugs in addition to isoniazid and rifampicin, further complicates treatment and management strategies. Efforts to control TB have been hampered by various challenges, including inadequate funding, weak healthcare infrastructure, limited access to diagnostics and treatment, and social stigma associated with the disease. The COVID-19 pandemic has further exacerbated these challenges, disrupting TB services, diverting resources, and exacerbating vulnerabilities among affected population.

PATHOPHYSIOLOGY

Tuberculosis (TB) is caused by infection with the bacterium *Mycobacterium tuberculosis*. This slow-growing, acid-fast bacillus primarily affects the lungs but can also involve other organs in the body. The pathophysiology of TB involves a complex interplay between the host immune response and the virulence factors of *M. tuberculosis*, leading to the characteristic clinical manifestations of the disease. Following inhaling *M. tuberculosis*-containing droplets, the bacteria are deposited in the lungs' alveoli, where alveolar macrophages engulf them. In most cases, the immune Response successfully contains the



infection at this stage, leading to the formation of granulomas, characteristic histological features of TB. Granulomas comprise a central core of infected macrophages surrounded by lymphocytes, epithelioid cells, and multinucleated giant cells. In some cases, the immune response may fail to contain the infection, leading to the progression from LTBI to active TB disease. This can occur due to factors such as immunosuppression (e.g., HIV/AIDS), malnutrition, diabetes, or aging. Active TB disease is characterized by the reactivation of dormant bacteria within the granuloma, leading to the destruction of lung tissue and the formation of cavities, which can serve as reservoirs for bacterial replication and dissemination.

The clinical manifestations of active TB disease depend on various factors, including the site and extent of infection, the immune status of the host, and the presence of underlying comorbidities. Pulmonary TB is the most common form of the disease, presenting with symptoms such as persistent cough, hemoptysis (coughing up blood), chest pain, and shortness of breath. Extrapulmonary TB can involve virtually any organ system, with manifestations such as lymphadenitis, pleuritis, meningitis, and disseminate

CAUSES OF TUBERCULOSIS

Tuberculosis (TB) is caused by infection with the bacterium *Mycobacterium tuberculosis*, also known as the tubercle bacillus. *M. tuberculosis* is a slow-growing, acid-fast bacillus that primarily affects the lungs but can also involve other organs in the body. TB is primarily transmitted through the inhalation of airborne droplets containing *M. tuberculosis*, typically expelled when an infected individual coughs, sneezes, or talks. This transmission mode underscores the significance of close human contact and shared airspace in facilitating the spread of the disease.

Several factors contribute to the transmission and spread of TB within populations. Overcrowded living conditions, poor ventilation, and inadequate healthcare infrastructure create ideal TB transmission environments. Individuals with active TB disease, particularly those with pulmonary involvement, are



highly infectious and can transmit the disease to others through close and prolonged contact.

SYMPTOMS OF TUBERCULOSIS

Tuberculosis (TB) manifests with a wide range of symptoms, which can vary depending on factors such as the site and extent of infection, the immune status of the host, and the presence of underlying comorbidities. The classic symptoms of pulmonary TB include a persistent cough lasting for more than two weeks, which may be productive of sputum that is often bloody or purulent . Other respiratory symptoms can include chest pain, difficulty breathing, and wheezing, particularly in cases where the infection involves the pleura or causes bronchial obstruction.

Systemic symptoms such as fever, night sweats, and fatigue are common in individuals with active TB disease. Fever may be low-grade or intermittent, often accompanied by chills and sweats, particularly at night . Night sweats, also known as nocturnal hyperhidrosis, can be profuse and drenching, leading to sleep disturbances and fatigue during the day.

In addition to respiratory and systemic symptoms, TB can also present with extrapulmonary manifestations involving other organ systems. Extrapulmonary TB can affect virtually any organ in the body, with common sites of involvement including the lymph nodes, bones and joints, central nervous system, and genitourinary tract

Symptoms of extrapulmonary TB can vary depending on the site of infection and may include localized pain, swelling, neurological deficits.

In children, TB symptoms can be more nonspecific and may include failure to thrive, poor weight gain, irritability, and developmental delay . Children with TB may also present with respiratory symptoms such as cough, wheezing, difficulty breathing and systemic symptoms such as fever, night sweats, and fatigue. Extrapulmonary TB is more common in children than in adults and can involve sites such as the lymph nodes, bones and joints, and central nervous system.



RISK FACTORS FOR TUBERCULOSIS

Several risk factors contribute to an individual's susceptibility to tuberculosis (TB) infection and progression to active disease. Immunocompromised conditions, such as infection with the human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS), significantly increase the risk of developing TB. HIV/AIDS weakens the immune system, making individuals more susceptible to TB infection and increasing the likelihood of TB reactivation in individuals with latent TB infection.

Diabetes mellitus is another crucial risk factor for TB, as individuals with diabetes are more susceptible to TB infection. Diabetes impairs immune function, particularly macrophage and T-cell function, which are crucial for controlling TB infection. Poorly controlled diabetes is associated with worse TB treatment outcomes and an increased risk of TB relapse and mortality.

Certain demographic factors, such as age and gender, also influence an individual's risk of TB infection and disease progression. TB incidence rates are highest among young adults aged 15-44 years, reflecting the social and economic factors driving TB transmission in this age group. However, TB can affect individuals of all ages, including children and older people. Men are generally at higher risk of TB than women, partly due to behavioral and occupational factors that increase exposure to TB infection.

DIAGNOSIS AND TREATMENT

Diagnosing tuberculosis (TB) requires a combination of clinical, radiological, and microbiological approaches to confirm the presence of active TB disease and guide appropriate treatment. Clinical evaluation involves a thorough medical history, physical examination, and assessment of risk factors for TB infection and disease progression. Common symptoms such as persistent cough, fever, night sweats, and weight loss raise suspicion for TB and warrant further investigation. Radiological imaging studies such as chest X-ray and computed tomography (CT) scans play a crucial role in diagnosing pulmonary TB. Chest X-ray findings suggestive of TB include the presence of pulmonary infiltrates, cavitation, and hilar or mediastinal lymphadenopathy. However, chest X-ray findings alone are



not diagnostic of TB and must be interpreted with clinical and microbiological findings. In addition to microbiological tests, immunological assays such as the tuberculin skin test (TST) and interferon -gamma release assays (IGRAs) can help identify individuals with latent TB infection (LTBI). These tests measure the immune response to *M. tuberculosis* antigens and indicate exposure to TB bacteria. However, they cannot differentiate between latent infection and active disease and must be interpreted in the context of clinical and radiological findings. First -line anti-TB drugs include isoniazid, rifampicin, pyrazinamide, and ethambutol, which are effective against drug-sensitive TB strains. Directly observed therapy (DOT) is recommended to ensure treatment adherence and minimize the risk of drug resistance.

Ensuring early diagnosis and prompt treatment initiation for individuals with active TB disease is crucial for preventing transmission and improving clinical outcomes. Access to diagnostic services such as sputum smear microscopy, culture, and molecular assays should be expanded to facilitate early case detection. Treatment should be initiated promptly following diagnosis, and directly observed therapy (DOT) should be implemented to ensure treatment adherence and minimize the risk of treatment failure and drug resistance.

Vaccination is an essential component of TB prevention and control efforts, particularly in high-burden settings where TB transmission is endemic. The Bacille Calmette-Guérin (BCG) vaccine, administered to infants soon after birth, provides partial protection against severe forms of TB, such as disseminated TB and TB meningitis in children. While the BCG vaccine is not highly effective in preventing pulmonary TB in adults, it remains an essential tool for reducing TB morbidity and mortality in children, particularly in settings with high TB incidence rates.

CONCLUSION

Tuberculosis (TB) remains a significant global health challenge, affecting millions of people worldwide and posing complex clinical, public health, and societal implications. Despite advancements in TB prevention, diagnosis, and treatment, TB continues to take a heavy toll on individuals, communities, and



healthcare systems, particularly in resource-limited settings and vulnerable populations. This comprehensive review has explored various aspects of TB, including its epidemiology, pathophysiology, clinical presentation, diagnosis, treatment, prevention, and control measures. We have examined TB's multifaceted nature, encompassing factors such as social determinants of health, TB-HIV co-infection, drug resistance, stigma, and the impact of climate change on TB transmission dynamics.

REFERENCES

1. Alemu A, Bitew ZW, Diriba G, Gumi B. Co-occurrence of tuberculosis and diabetes mellitus, and associated risk factors, in Ethiopia: A systematic review and meta-analysis.
2. Centers for Disease Control and Prevention. Tuberculosis and HIV coinfection; 2021. Available: <https://www.cdc.gov/tb/topic/basics/tbhivcoinfection.htm>
3. Boima V, Dey ID. The Bidirectional Relationship between Tuberculosis and Diabetes. *Tuberc Res Treat.* 2017;2017:1702578.
4. Zeru MA. Prevalence and associated factors of HIV-TB coinfection among HIV patients: A retrospective Study. *Afr Health Sci.* 2021;21(3):1003-1009. DOI: 10.4314/ahs.v21i3.7
5. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva: World Health Organization; 2013.
6. UN. General Assembly (73rd sess. : 2018-2019). Political declaration of the high-level meeting of the general assembly on the fight against tuberculosis: resolution/adopted by the general assembly. New York:
7. Narmetova, Y., Kuldosheva, G., & Bekmirov, T. (2021). The Psychological Services Role in the Psychodiagnostics and Psychocorrection of Psychosomatic Patients in the Psychoemotional Situation. *International Journal of Multicultural and Multireligious Understanding*, 8(12), 249-256.



Modern American Journal of Medical and Health Sciences

ISSN (E): 3067-803X

Volume 01, **Issue** 08, November, 2025

Website: usajournals.org

This work is Licensed under CC BY 4.0 a Creative Commons Attribution 4.0 International License.

-
8. Karimovna, N. Y., Nasirovna, M. R., Tursunaliyevna, A. M., Abduvaliyevna, A. N., & Ravshanovna, U. S. (2023). Psychodiagnostics of psychosomatic diseases. Journal of survey in fisheries sciences, 10(2S), 2903-2911.
 9. Narmetova, Y. (2024). COMPARATIVE ANALYSIS OF THE PSYCHOLOGICAL STATE AND SOCIO-PSYCHOLOGICAL CHARACTERISTICS OF PATIENTS WITH PSYCHOSOMATIC DISEASES. Current approaches and new research in modern sciences, 3(3), 83-87.
 10. Yunusova, M. R., Rakhimbaeva, G. S., & Narmetova, Y. K. (2025). COGNITIVE IMPAIRMENT IN MULTIPLE SCLEROSIS. Academic research in educational sciences, (Conference), 80-85.